Impedance‐Controlled Multipoint Radiofrequency Ablation for Chronic Rhinitis: A Randomized Controlled Trial
International Forum of Allergy & Rhinology · 2026-06 · 16 (6) · 553-560
DOI: 10.1002/alr.70101 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Forum of Allergy & Rhinology, online erschienen am 08.01.2026. Verfasst von Masayoshi Takashima und 5 weiteren Autor:innen. Beteiligte Einrichtung: Houston Methodist Hospital, Houston, Texas, USA. Hauptthemen laut MEDLINE: Radiofrequency Ablation, Rhinitis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Neurent Medical.
Abstract (Originalsprache)
Background
The purpose of this randomized controlled trial (RCT) was to demonstrate that posterior nasal nerve ablation treatment with the NEUROMARK System is superior to a sham control procedure in patients with chronic rhinitis.
Methods
In this prospective, multicenter, single‐blinded, superiority RCT, 132 participants were randomized 2:1 to the active treatment arm (88) and sham control arm (44). The primary endpoint was the comparison of the reflective Total Nasal Symptom Score (rTNSS) responder rate between study arms at 90‐day follow‐up. Secondary efficacy outcomes included postnasal drip, chronic cough, Nasal Obstruction Symptom Evaluation (NOSE), mini‐Rhinoconjunctivitis Quality of Life Questionnaire (mini‐RQLQ), and Patient Health Questionnaire‐9 (PHQ‐9) (a depression assessment).
Results
The responder rate was significantly higher for the active treatment arm: 73.3% (95% confidence interval [CI], 64.0%–82.7%) compared to the sham control arm: 35.0% (95% CI, 20.2%–49.8%; p < 0.001). The primary endpoint was met, demonstrating the active treatment arm is superior to the sham control arm. The active treatment arm had significantly greater decreases (improvements) in the rTNSS (–4.0 vs. –1.2, p < 0.0001), postnasal drip (–1.1 vs. –0.3, p < 0.001), cough (–0.9 vs. –0.1, p < 0.001), NOSE score (–32.2 vs. –8.0, p < 0.0001), mini‐RQLQ (–1.7 vs. –0.5, p < 0.0001), and PHQ‐9 (–3.0 vs. –0.7, p = 0.028), compared to the sham control arm. The NOSE responder rate and mini‐RQLQ responder rate were significantly higher for the active treatment arm than the sham control arm ( p = 0.001 and p < 0.0001, respectively).
Conclusion
Treatment for chronic rhinitis with the NEUROMARK System is superior to sham control.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Houston Methodist Hospital, Houston, Texas, USA.
- Sacramento Ear Nose and Throat Medical and Surgical Group, Roseville, California, USA.
- ENT & Allergy Centers of Texas, McKinney, Texas, USA.
- O'Malley Medical Communications, LLC, Victoria, Minnesota, USA.
- East Alabama Ear, Nose and Throat, PC, Opelika, Alabama, USA.
ORCID-Profile: Ellen M O'Malley
Förderung
- Neurent Medical
Zitieren
APA
Takashima, M., Ow, R. A., Thrasher, R. D., O'Malley, E. M., Blythe, W. R., & Ahmed, O. G. (2026). Impedance‐Controlled Multipoint Radiofrequency Ablation for Chronic Rhinitis: A Randomized Controlled Trial. International Forum of Allergy & Rhinology, 16(6), 553-560. https://doi.org/10.1002/alr.70101
Vancouver
Takashima M, Ow RA, Thrasher RD, O'Malley EM, Blythe WR, Ahmed OG. Impedance‐Controlled Multipoint Radiofrequency Ablation for Chronic Rhinitis: A Randomized Controlled Trial. International Forum of Allergy & Rhinology. 2026;16(6):553-560. doi:10.1002/alr.70101
BibTeX
@article{Takashima2026,
author = {Takashima, Masayoshi and Ow, Randall A and Thrasher, Richard D and O'Malley, Ellen M and Blythe, William R and Ahmed, Omar G},
title = {Impedance‐Controlled Multipoint Radiofrequency Ablation for Chronic Rhinitis: A Randomized Controlled Trial},
journal = {International Forum of Allergy & Rhinology},
year = {2026},
volume = {16},
number = {6},
pages = {553--560},
doi = {10.1002/alr.70101}
}
EUVIMED